{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T18:52:05Z","timestamp":1781376725512,"version":"3.54.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"43","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.vaccine.2019.08.025","type":"journal-article","created":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T17:17:41Z","timestamp":1567790261000},"page":"6558-6565","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Twelve years of pneumococcal conjugate vaccination in the Netherlands: Impact on incidence and clinical outcomes of invasive pneumococcal disease"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7265-8886","authenticated-orcid":false,"given":"Stefan M.T.","family":"Vestjens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth A.M.","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart J.","family":"Vlaminckx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hester E.","family":"de Melker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arie","family":"van der Ende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam J.","family":"Knol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.08.025_b0005","unstructured":"European Centre for Disease Prevention and Control (ECDC). Disease factsheet about pneumococcal disease n.d. <https:\/\/ecdc.europa.eu\/en\/pneumococcal-disease\/facts> (accessed December 7, 2018)."},{"key":"10.1016\/j.vaccine.2019.08.025_b0010","unstructured":"World Health Organization (WHO). Vaccines and diseases|Pneumococcal disease 2014."},{"key":"10.1016\/j.vaccine.2019.08.025_b0015","unstructured":"European Centre for Disease Prevention and Control (ECDC). Vaccine schedules in all countries of the European Union n.d. <https:\/\/vaccine-schedule.ecdc.europa.eu\/> (accessed April 11, 2018)."},{"key":"10.1016\/j.vaccine.2019.08.025_b0020","unstructured":"World Health Organization (WHO). WHO vaccine-preventable diseases: monitoring system. 2018 global summary 2018. <http:\/\/apps.who.int\/immunization_monitoring\/globalsummary\/schedules> (accessed December 7, 2018)."},{"key":"10.1016\/j.vaccine.2019.08.025_b0025","unstructured":"National Institute for Public Health and the Environment (RIVM). Immunisation coverage and annual report National Immunisation Programme in the Netherlands 2017 2018. <https:\/\/www.rivm.nl\/publicaties\/vaccinatiegraad-en-jaarverslag-rijksvaccinatieprogramma-nederland-2017> (accessed December 7, 2018)."},{"key":"10.1016\/j.vaccine.2019.08.025_b0030","series-title":"Pneumococcal vaccine in elderly adults and risk groups","author":"Health Council of the Netherlands","year":"2003"},{"key":"10.1016\/j.vaccine.2019.08.025_b0035","unstructured":"Medication and medical tools Information Project (GIP). Number of DDDs by age and gender for ATC code J07AL01 \u2013 purified pneumococcal polysaccharide antigen in 2017. Number DDDs by Age Gend ATC Code J07AL01 \u2013 purified pneumococcal polysacch antigen 2017 2018. <https:\/\/www.gipdatabank.nl\/databank#\/g\/\/B_03-lftgesl\/ddd\/J07AL01> (accessed December 19, 2018)."},{"key":"10.1016\/j.vaccine.2019.08.025_b0040","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.3201\/eid2111.140780","article-title":"Invasive pneumococcal disease 3 years after introduction of 10-valent pneumococcal conjugate vaccine, the Netherlands","volume":"21","author":"Knol","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2019.08.025_b0045","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.vaccine.2015.12.066","article-title":"Invasive pneumococcal disease: clinical outcomes and patient characteristics 2\u20136 years after introduction of 7-valent pneumococcal conjugate vaccine compared to the pre-vaccine period, the Netherlands","volume":"34","author":"Wagenvoort","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.08.025_b0050","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S1473-3099(18)30052-5","article-title":"Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000\u201317: a prospective national observational cohort study","volume":"18","author":"Ladhani","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2019.08.025_b0055","first-page":"699","article-title":"The quellung reaction, a neglected microbiologic technique","volume":"43","author":"Austrian","year":"1976","journal-title":"Mt Sinai J Med"},{"key":"10.1016\/j.vaccine.2019.08.025_b0060","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.3201\/eid1811.120329","article-title":"Invasive pneumococcal disease and 7-valent pneumococcal conjugate vaccine, the Netherlands","volume":"18","author":"van Deursen","year":"2012","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2019.08.025_b0065","doi-asserted-by":"crossref","first-page":"816","DOI":"10.3201\/eid1605.091223","article-title":"Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands","volume":"16","author":"Rodenburg","year":"2010","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2019.08.025_b0070","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1080\/14760584.2018.1413354","article-title":"Public health impact of pneumococcal conjugate vaccine infant immunization programs: assessment of invasive pneumococcal disease burden and serotype distribution","volume":"17","author":"Izurieta","year":"2018","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2019.08.025_b0075","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1016\/j.vaccine.2018.03.001","article-title":"Long-term impact of 10-valent pneumococcal conjugate vaccination on invasive pneumococcal disease among children in Finland","volume":"36","author":"Rinta-Kokko","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.08.025_b0080","article-title":"Effect of childhood pneumococcal conjugate vaccination on invasive disease in older adults of 10 European countries: implications for adult vaccination","author":"Hanquet","year":"2018","journal-title":"Thorax"},{"key":"10.1016\/j.vaccine.2019.08.025_b0085","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1093\/cid\/cix685","article-title":"Comparison of the impact of pneumococcal conjugate vaccine 10 or pneumococcal conjugate vaccine 13 on invasive pneumococcal disease in equivalent populations","volume":"65","author":"Naucler","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.08.025_b0090","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1473-3099(18)30346-3","article-title":"Switch in a childhood pneumococcal vaccination programme from PCV13 to PCV10: a defendable approach?","volume":"18","author":"Desmet","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2019.08.025_b0095","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1097\/INF.0000000000001845","article-title":"Characteristics of children with invasive pneumococcal disease after the introduction of the 13-valent pneumococcal conjugate vaccine in England and Wales, 2010\u20132016","volume":"37","author":"Makwana","year":"2018","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2019.08.025_b0100","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3201\/eid1901.120741","article-title":"Invasive pneumococcal disease after routine pneumococcal conjugate vaccination in children, England and Wales","volume":"19","author":"Ladhani","year":"2013","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2019.08.025_b0105","unstructured":"World Health Organization (WHO). Pneumococcal conjugate vaccines in infants and children under 5 years of age: WHO position paper \u2013 February 2019 title. Wkly Epidemiol Rec 2019."},{"key":"10.1016\/j.vaccine.2019.08.025_b0110","doi-asserted-by":"crossref","first-page":"e0192640","DOI":"10.1371\/journal.pone.0192640","article-title":"Impact and cost-effectiveness of different vaccination strategies to reduce the burden of pneumococcal disease among elderly in the Netherlands","volume":"13","author":"Thorrington","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.08.025_b0115","unstructured":"Health Council of the Netherlands. Pneumococcal vaccination in elderly adults ('advies Vaccinatie van ouderen tegen pneumokokken\u2019). 2018."},{"key":"10.1016\/j.vaccine.2019.08.025_b0120","unstructured":"ClinicalTrials.gov. A study to evaluate the safety, tolerability, and immunogenicity of V114 followed by PNEUMOVAXTM23 in adults infected with human immunodeficiency virus (HIV) (V114-018\/PNEU-WAY) \u2013 full text view \u2013 ClinicalTrials.gov n.d. <https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03480802> (accessed December 7, 2018)."},{"key":"10.1016\/j.vaccine.2019.08.025_b0125","unstructured":"ClinicalTrials.gov. Trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-na\u00efve adults \u2013 full text view \u2013 ClinicalTrials.gov n.d. <https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03760146> (accessed December 7, 2018)."},{"key":"10.1016\/j.vaccine.2019.08.025_b0130","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa1408544","article-title":"Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults","volume":"372","author":"Bonten","year":"2015","journal-title":"N Engl J Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19310758?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19310758?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:37:34Z","timestamp":1759401454000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19310758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":26,"journal-issue":{"issue":"43","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0264410X19310758"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.08.025","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Twelve years of pneumococcal conjugate vaccination in the Netherlands: Impact on incidence and clinical outcomes of invasive pneumococcal disease","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.08.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}